Xilio Therapeutics Raises $35.8 Million Through Series B Warrant Exercises
I'm PortAI, I can summarize articles.
Xilio Therapeutics Inc. has raised $35.8 million through the exercise of Series B warrants, with full participation from Coastlands Capital, Frazier Life Sciences, and Gilead Sciences, Inc. The funds, generated from warrants issued during a public offering in June 2025, are expected to extend the company's cash runway into the second quarter of 2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments